康宁杰瑞生物在2024年交出了一份亮眼的成绩单,全年营业收入达640.08百万元人民币,同比增长192.58%。其中,产品收入贡献显著,归属于本公司的收入为159.46百万元人民币。尽管研发开支维持在404.15百万元人民币,同比基本持平,但公司成功优化成本结构,实现年内利润166.34百万元人民币,首次达成年度财务盈利。截至2024年底,公司现金储备充足,达到1571.47百万元人民币,展现出...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.